FDA Approves Ascendis Pharma's Yorvipath (Palopegteriparatide; Developed As TransCon PTH) For Hypoparathyroidism In Adults, Ascendis Is Completing Manufacturing Of Commercial Product For The U.S. Market And Anticipates Initial Supply Will Be Available In Q1 Of 2025
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Ascendis Pharma's Yorvipath (Palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults. Ascendis is finalizing the manufacturing process for the U.S. market and expects the initial supply to be available in Q1 of 2025.
August 12, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA approval of Ascendis Pharma's Yorvipath for hypoparathyroidism is a significant milestone. The company is finalizing manufacturing and expects the initial supply to be available in Q1 2025.
FDA approval is a critical regulatory milestone that can significantly boost investor confidence and potentially drive the stock price up. The anticipation of the initial supply in Q1 2025 indicates a clear timeline for market entry, which is positive for future revenue projections.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100